Skip to content

Home
About Us
- Board of Directors
- Management Team
Technology
News/Resources
Investor Centre
Contacts

ASX Announcements 2022

24 Nov 2022
Supplementary Prospectus
24 Nov 2022
Rights Issue Closed
18 Nov 2022
R&D Tax Incentive
16 Nov 2022
Results of Annual General Meeting
11 Nov 2022
Presentation to Investors
31 Oct 2022
Commencement of Rights Trading on ASX
31 Oct 2022
Shareholder Update
27 Oct 2022
Entitlement Issue Prospectus
27 Oct 2022
Renounceable Rights Issue to Raise up to $4.2 Million
27 Oct 2022
Proposed Issue of Securities
24 Oct 2022
Report on Activities for the Quarter Ended 30 September 2022
24 Oct 2022
Quarterly Report 30 September 2022
14 Oct 2022
Annual Report and Notice of AGM
4 Oct 2022
Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
14 Sep 2022
BIT225 COVID-19 Human Study Commenced
23 Aug 2022
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
19 Aug 2022
Year End Accounts and Preliminary Final Report
19 Aug 2022
Appendix 4G and Corporate Governance Statement 2022
28 Jul 2022
Report on Activities for the Quarter Ended 30 June 2022
28 Jul 2022
Quarterly Report 30 June 2022
30 May 2022
Positive FDA Guidance for COVID-19 Clinical Program
2 May 2022
BIT225 Effective Against Established SARS-CoV-2 in Animals
26 Apr 2022
Report on Activities for the Quarter Ended 31 March 2022
26 Apr 2022
Quarterly Report 31 March 2022
5 Apr 2022
R&D Tax Incentive
17 Mar 2022
Confirmation of BIT225 Effectiveness Against COVID-19 in Animals
23 Feb 2022
Half-year Report 31 December 2021
28 Jan 2022
Report on Activities for the Quarter Ended 31 December 2021
28 Jan 2022
Quarterly Report 31 December 2021

<<
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
>>

Investor Centre

Investor Centre

© Biotron Limited 2016 ABN 60 086 399 144 Site updated 23 November 2023 Legal Notices and Privacy